# 1 Identification of a *de novo* mutation in *TLK1* associated with a neurodevelopmental 2 disorder and immunodeficiency

3

Marina Villamor-Payà<sup>1,2</sup>, María Sanchiz-Calvo<sup>1,#</sup>, Jordann Smak<sup>2</sup>, Lynn Pais<sup>3,4</sup>, Malika Sud<sup>4</sup>,
Uma Shankavaram<sup>2</sup>, Alysia Kern Lovgren<sup>4</sup>, Christina Austin-Tse<sup>4</sup>, Vijay S Ganesh<sup>4,5</sup>, Marina
Gay<sup>1</sup>, Marta Vilaseca<sup>1</sup>, Gianluca Arauz-Garofalo<sup>1</sup>, Lluís Palenzuela<sup>1</sup>, Grace VanNoy<sup>3,4</sup>, Anne
O'Donnell-Luria<sup>3,4</sup> and Travis H. Stracker<sup>1,2</sup>.

- 8
- 9 10
- 11 Affiliations
- <sup>1</sup>Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and
- 13 Technology, Barcelona 08028, Spain
- <sup>14</sup> <sup>2</sup>National Cancer Institute, Center for Cancer Research, Radiation Oncology Branch, Bethesda,
- 15 MD 20892, USA.
- <sup>16</sup> <sup>3</sup>Division of Genetics & Genomics, Department of Pediatrics, Boston Children's Hospital,
- 17 Boston, MA 02115, USA.
- <sup>4</sup>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge,
   MA 02142, USA.
- <sup>5</sup>Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
- #Current affiliation: Laboratory for Neurobiology and Gene Therapy, Department of
   Neurosciences, Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium
- 23

25 26

24 \*Lead Contact: travis.stracker@nih.gov

27 Running title: *TLK1*-associated neurodevelopmental disorder

28
29 Keywords: Neurodevelopmental disorder, microcephaly, immunodeficiency, TLK1, TLK2,
30 STAT3
31
32

- 33
- 34
- 35
- 36 37
- 38
- 39
- 40
- 41
- 42

#### 43

## 44 Abstract

#### 45 Background

The Tousled-like kinases 1 and 2 (TLK1/TLK2) regulate DNA replication, repair and chromatin maintenance. TLK2 variants are associated with 'Intellectual Disability, Autosomal Dominant 57' (MRD57), a neurodevelopmental disorder (NDD) characterized by intellectual disability (ID), autism spectrum disorder (ASD) and microcephaly. Several TLK1 variants have been reported in NDDs but their functional significance is unknown.

## 51 Methods

A male patient presenting with ID, seizures, global developmental delay, hypothyroidism, and primary immunodeficiency was determined to have a novel, heterozygous variant in TLK1 (c.1435C>G, p.Q479E) by genome sequencing (GS). Single cell gel electrophoresis, western blot, flow cytometry and RNA-seq were performed in patient-derived lymphoblast cell lines. In silico, biochemical and proteomic analysis were used to determine the functional impact of the p.Q479E variant and previously reported NDD-associated TLK1 variant, p.M566T.

#### 58 Results

59 Transcriptome sequencing in patient-derived cells confirmed expression of TLK1 transcripts 60 carrying the p.Q479E variant and revealed alterations in genes involved in class switch 61 recombination and cytokine signaling. Cells expressing the p.Q479E variant exhibited reduced 62 cytokine responses and higher levels of spontaneous DNA damage but not increased sensitivity 63 to radiation or DNA repair defects. The p.Q479E and p.M566T variants impaired kinase activity 64 but did not strongly alter localization or proximal protein interactions.

#### 65 **Conclusion**

66 Our study provides the first functional characterization of TLK1 variants associated with NDDs 67 and suggests potential involvement in central nervous system and immune system

development. Our results indicate that, like TLK2 variants, TLK1 variants may impact
 development in multiple tissues and should be considered in the diagnosis of rare NDDs.

#### 70 Introduction

71 The Tousled-like kinases 1 and 2 (TLK1 and TLK2) are conserved serine-threonine kinases that 72 function in numerous cellular processes, including DNA replication, DNA repair, transcription 73 and chromatin maintenance(1). Both TLK1 and TLK2 interact with and regulate the ASF1A and 74 ASF1B histone H3-H4 chaperones(2–7). Depletion of both TLK1 and TLK2, or both ASF1A and 75 ASF1B, led to overlapping cellular phenotypes, including DNA damage, innate immune 76 activation and the induction of the alternative lengthening of telomeres (ALT) pathway(8-10). 77 TLK1 and TLK2 are regulated by the DNA damage response and the phosphorylation of TLK1 78 on its C-terminus by the checkpoint kinase CHK1 inhibits TLK1 activity(11,12). TLK1 also 79 phosphorylates the RAD9 protein, part of the RAD9-RAD1-HUS1 (9-1-1) complex that responds 80 to DNA damage and regulates CHK1 activity, as well as the NEK1 kinase, that is involved in the 81 DNA damage response and ciliogenesis(4,13–19).

82

83 Despite clear associations with fundamental cellular processes and multiple links to the DNA 84 damage response, Tlk1 deficiency in mice did not result in any overt phenotypes. Notably, both 85 immune system development and fertility were grossly normal, suggesting DNA repair-86 dependent processes in V(D)J recombination and meiosis were functional(8). Additionally, the 87 deletion of TLK1 in hundreds of cancer cell lines did not strongly influence cell fitness(20). In 88 contrast, loss of *Tlk2* in mice led to embryonic lethality due to a role in placental development, 89 and TLK2 is an commonly essential gene in many cancer cell lines, indicating distinct functions 90 or regulation that remain to be fully understood(8,20).

91

Variants in *TLK2* have been implicated in Intellectual Developmental Disorder, Autosomal
 Dominant 57 (MRD57, MIM# 618050), a heterogenous neurodevelopmental disorder (NDD)

94 characterized by intellectual disability (ID), autism spectrum disorder (ASD), microcephaly, 95 additional behavioral problems, growth delay and facial dysmorphism, including 96 blepharophimosis, telecanthus, prominent nasal bridge, broad nasal tip, thin vermilion of the 97 upper lip and upslanting palpebral fissures(21-25). A subset of cases also exhibited 98 gastrointestinal problems, seizures, skeletal malformations and ocular problems. With one 99 exception, all of the disease-associated TLK2 variants identified to date are heterozygous, and 100 those examined biochemically showed diminished kinase activity, suggesting pathological 101 outcomes are largely due to reduced kinase activity(23.24).

102

Activation of TLK2 requires dimerization through its first coiled-coil (CC1), which is also required for its heterodimerization with TLK1(26,27). As TLK1 and TLK2 interact, some of the identified TLK2 missense variants may exert dominant negative effects on wild type TLK2 and potentially TLK1(28). While >40 TLK2 variants have been identified in NDD patients, to date, only four *de novo TLK1* variants have been associated with NDDs (Table 1)(21–25,29). However, no causal links have been established, and the effects of any of the individual variants on protein function have not been investigated.

110

Here we report the identification of a male proband who presented with microcephaly, ID, seizures, global developmental delay, cerebral calcifications, feeding difficulties, growth hormone deficiency, hypothyroidism, urticaria and primary immunodeficiency. He had extensive prior genetic testing, including whole exome sequencing (WES), that did not identify a clear genetic cause for his phenotype. Subsequent research exome sequencing (ES) and genome sequencing (GS) through the Rare Genomes Project (RGP) identified heterozygous, *de novo* variants in *TLK1* c.1435C>G (p.Q479E) and *MDM1* c.1197dupT (p.K400Ter).

TLK1 variant	TLK1 protein	Disease association	Reference

c.74C>T	p.P25L	Intellectual disability	(25)
c.112_113del	p.T38fs	Intellectual disability	<u>ClinVar</u>
c.424G>A	p.R142S	Limb, ear, eye and muscle abnormalities	DECIPHER
c.1101del	p.K367Nfs*	Schizophrenia	(30)
c.1435C>G	p.Q479E	Intellectual disability, microcephaly, immunodeficiency	This study
c.1697T>C	p.M566T	Autism Spectrum Disorder	(29)
c.1796C>G	p.A599G	Congenital heart defect	(31)

119

Table 1: List of *TLK1* variants reported with links to human disease. Positions are based on
 <u>NM\_012290.5</u>.

#### 123 Materials and Methods

## 124 Genome sequencing (GS), variant calling, and prioritization

125 GS and data processing for this individual and his parents were performed by the Genomics 126 Platform at the Broad Institute of MIT and Harvard. PCR-free preparation of sample DNA (350 127 ng input at >2 ng/uL) was accomplished using Illumina HiSeq X Ten v2 chemistry. Libraries 128 were sequenced to a mean target coverage of >30X. WGS data was processed through a 129 pipeline based on Picard, using base quality score recalibration and local realignment at known 130 indels. The BWA aligner was used for mapping reads to the human genome build 38. Single 131 Nucleotide Variants (SNVs) and insertions/deletions (indels) were jointly called across all 132 samples using the Genome Analysis Toolkit (GATK) HaplotypeCaller package version 4.0. 133 Default filters were applied to SNV and indel calls using the GATK Variant Quality Score 134 Recalibration (VQSR) approach. Annotation was performed using Variant Effect Predictor 135 (VEP). GATK-SV(32) was used to detect structural variants (SVs), which were annotated with 136 the GATK SVAnnotate tool. Mitochondrial DNA (mtDNA) single nucleotide and small indel 137 variants were called from GS data using the gnomAD-mitochondria pipeline(33) and large 138 mtDNA deletions were called by MitoSAlt(34). ExpansionHunter v5 was used to genotype 139 known disease-associated short tandem repeats (STRs)(35). Lastly, the variant call set was

- 140 uploaded to seqr for analysis by the RGP team. Variants in *TLK1* (p.Gln479Glu) and *MDM1*
- 141 (p.Lys400Ter) were submitted to ClinVar (submission ID: SUB13580789).
- 142

## 143 Cell culture and generation of patient cell lines

144 Peripheral blood mononuclear cells were isolated from whole blood using Histopaque-1077 145 (Sigma-Aldrich) and subsequently immortalized with Epstein-Barr virus transformation (Coriell 146 Institute). Lymphoblastoid cell lines were cultured in RPMI-1640 medium (Corning) 147 supplemented with 15% fetal bovine serum (FBS) (Gibco), 1% penicillin-streptomycin, and 2 148 mM L-glutamine. AD-293 cells (Stratagene) were grown in DMEM supplemented with 10% FBS 149 (Sigma-Aldrich), 50 U/mL penicillin and 50 µg/mL streptomycin (Thermo Fisher Scientific) and 150 authenticated using STR testing (ATCC). All cells were kept at 37°C in a 5% CO<sub>2</sub> incubator. 151 Cells were counted with a Countess cell counter (Invitrogen) and viability was assessed using 152 trypan blue. For any given experiment, only cell cultures with a viability >90% were used. Cells 153 were routinely tested for mycoplasma and found negative (Lonza).

154

#### 155 Genomic DNA and RNA Purification

Genomic DNA was purified from **lymphoblastoid cell lines** using the Gentra Puregene Cell kit (Qiagen) following manufacturer's instructions. Total RNA was extracted from lymphoblastoid cell lines (LCLs) using the SV Total RNA Isolation System (Promega) following manufacturer's instructions. Full methods provided in **online supplemental materials and methods**.

160

#### 161 **PCR amplification and DNA extraction from agarose gels**

Genomic DNA was subjected to 35 cycles of PCR amplification using Q5 High-Fidelity DNA Polymerase (New England Biolabs) with primers that allow for the amplification of the region containing the variants of interest (**online supplemental table S1**). PCR products were run in a 2% agarose gel and purified using the Nucleospin Gel and PCR clean-up kit (Macherey-

166 Nagel) following manufacturer's instructions. Full methods provided in **online supplemental** 

- 167 materials and methods.
- 168

## 169 Nextera library preparation and sequence analysis for variant calling in PCR products

DNA libraries were prepared using the Nextera XT DNA Library Prep kit (Illumina) following manufacturer's instructions. Sequencing of PCR amplicons was carried out using the MiSeq Nano kit sequencing system (Illumina) with 150 bp paired-end (PE) reads. Cleaned reads were obtained by Trim Galore and FASTQ sequences aligned to the hg38 genome build followed by BCFtools for variant calling and alternate allele frequency of the sequenced genes(36). A filter

- 175 with quality score >=20 was used to remove variants likely observed purely by chance.
- 176

## 177 RNA sequencing (RNA-seq)

178 RNA-seg was performed in the CCR Genomics core facility. RNA-seg data processing was 179 performed RNA-seq using the pipelines of the CCBR Pipeliner framework 180 (https://github.com/CCBR/Pipeliner). Full analysis methods provided in online supplemental 181 materials and methods. Data was submitted to GEO: GSE241032.

182

## 183 In silico prediction and modeling of missense variants

*In silico* prediction of variants was analyzed using seqr (https://seqr.broadinstitute.org)(37). Residue conservation was determined using ConSurf (https://consurf.tau.ac.il)(38) and the heatmap generated using Prism. The TLK1 kinase domain structure was generated using Alphafold (https://alphafold.ebi.ac.uk) and color modified in PyMol to indicate residues of interest.

189

### 190 **Comet and cell proliferation assays**

191 Comet assays were performed according to manufacturer's instructions (Trevigen). Proliferation 192 was assessed using the Click-iT Plus EdU Flow Cytometry Assay Kit (Invitrogen) following 193 manufacturer's instructions. Full methods provided in **online supplementary materials and** 194 **methods.** 

195

Cloning, site-directed mutagenesis, transfection, streptavidin affinity purification,
 western blotting and kinase assays

198 Cloning, mutagenesis, transfections, western blotting, streptavidin affinity purification of TLK1 199 from cell lysates and *in vitro* kinase assays were performed as previously described with minor 200 variations(24). Full methods are provided in the online supplemental materials and methods. 201 Primers are provided in online supplementary table S1, antibodies are provided in online 202 supplementary table S2 and uncropped westerns including those used for quantification are 203 shown in **online supplementary figure S1.** Westerns and gels used for kinase assays are 204 shown in online supplementary figure S2. Proteomic data is available in the PRIDE 205 repository: PXD019450.

206

207 **Results** 

208 Identification of a proband with a neurodevelopmental disorder and a *de novo TLK1* 209 variant

After an uncomplicated pregnancy, the proband was born with microcephaly noted early in the postnatal period. Between 0-5 months of age, he was admitted to the neonatal intensive care unit (NICU) due to an infection that progressed to respiratory failure. During a several month course in the NICU, he was found to have B- and T-cell deficiency and diagnosed with primary hypothyroidism (TSH 33 ulU/mL, repeat 18.6 ulU/mL). At less than 5 months old, he had a stroke and a generalized seizure and was treated with levetiracetam, after which he was weaned off levetiracetam. Brain MRI revealed symmetric periventricular and subcortical

217 leukoencephalopathy with mild cystic white matter encephalomalacia, ex vacuo
218 ventriculomegaly, thinning of the corpus callosum, and bilateral optic nerve atrophy (Figure 1A219 D.

T cells normalized before 5 years of age, but he still has B-cell deficiency and hypogammaglobulinemia (low IgG), treated with weekly subcutaneous immunoglobulin. Enzymatic testing for severe combined immunodeficiency (SCID), including adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP), was normal (age 0).

Between 15 and 20 months, he had a kidney biopsy following episodes of proteinuria and hematuria that was not diagnostic. Between 6 and 10 years old, he was diagnosed with growth hormone deficiency and treated with growth hormone injections.

His medical history is also notable for significant global developmental delay, hypotonia, mild outer retinal dystrophy, feeding difficulties, and skin findings including poikiloderma, annular urticaria, and a chronic rash that flares up upon infection. He has used a walker for support from 15-20 months of age and has significant speech and language delays, though his receptive abilities are more developed than his expressive language.

The proband had thorough clinical genetic testing, all of which came back normal. This included chromosomal microarray and karyotyping, candidate-gene sequencing (*CIAS1, RAB27A, RECQL4*), targeted mutation analysis (Factor V Leiden p.R506Q, Factor II/prothrombin p.G20210A), mtDNA analysis and nuclear mitochondrial disease panel, and panel testing (SCID panel, Aicardi Gouitéres panel, Noonan syndrome panel, dyskeratosis congenita panel). Clinical exome sequencing (ES) and subsequent ES reanalysis in 2017 were negative.

Research GS done through RGP identified a rare *de novo* frameshift variant in *MDM1*(c.1197dupT; p.Lys400Ter; 12:68315249, hg38) and a rare *de novo* missense variant in *TLK1*(c.1435C>G; p.Gln479Glu; 2:171007045, hg38) further detailed in this report.



241

Figure 1: T2/FLAIR axial (A, B), sagittal (C), and coronal (D) sections from age 10-15 years shows symmetric periventricular and subcortical leukoencephalopathy with mild cystic white matter encephalomalacia, ex vacuo ventriculomegaly, and thin corpus callosum.

245

## 246 Characterization of patient-derived cells expressing the *TLK1* and *MDM1* variants

To further investigate the potential impact of the mutations, PBMCs from the proband and an unaffected female sibling of a similar age, were isolated and transformed with Epstein Barr Virus (EBV) to generate lymphoblastoid cell lines (LCLs). Genomic DNA from expanded LCLs was

amplified with specific primers, and sequencing confirmed the presence of both the *TLK1* and
 *MDM1* variants identified by GS.

252

253 We next performed RNA-seq on each LCL to identify differentially expressed genes (DEGs) and 254 assess the expression levels of the specific variant alleles of both MDM1 and TLK1. Both TLK1 255 and MDM1 were expressed to similar levels in each cell line (Figure 2A and online 256 supplementary table S3). The allele harboring the TLK1 variant was transcribed to a similar 257 extent as the wildtype allele (Figure 2B and online supplementary table S4), and quantitative 258 western blotting showed total TLK1 protein levels slightly elevated in cells from the proband with 259 the p.Q479E variant compared to the unaffected sibling (Figure 2C). In contrast to the TLK1 260 variant, the MDM1 mutant allele was not detectably expressed, likely indicating nonsense-261 mediated RNA decay (NMD) (Figure 2B). However, total MDM1 protein levels appeared similar, 262 consistent with RNA-seg data, suggesting that MDM1 protein levels are unaffected in the LCL 263 line (Figure 2D). We next examined the phosphorylation of two reported TLK1 substrates 264 ASF1A and NEK1(6,17). In both cases, no significant difference in phosphorylation of either 265 substrate could be observed between the cell lines (Figure 2E-F).







levels and quantification of western blots (N=3) is shown in right panel. N represents biological
replicates, statistical significance was determined using an unpaired t test with Welch's
correction (\*P<0.05) in panels C,D.</li>

280

## 281 Gene expression differences consistent with immunodeficiency

282 RNA-seq data was further analyzed to identify DEGs between the LCL cell lines (Figure 3A). 283 Ingenuity pathway analysis (IPA) identified Primary Immunodeficiency Signaling (PID) as a top 284 enriched category, consistent with the immunodeficiency of the proband (Figure 3A-C). Many of 285 the genes identified are involved in class switch recombination (CSR), and additional DEGs in 286 CSR genes were identified manually, including CD27 and FCRL3 (Online supplemental table 287 S3). In addition, the STAT3 pathway, Osteoarthritis pathway (OSTEO) and Hepatic fibrosis 288 pathways were among the top 4 significantly altered pathways in the LCLs of the proband 289 compared to the sibling (Figure 3A-C). Notably, these pathways included a number of 290 transcriptional regulators, cytokines and other cell surface proteins that influence cell to cell 291 interactions in the immune system.

292

293 Examination of the STAT3 signaling related genes revealed a number of DEGs, including the 294 Interleukin-6 receptor (IL6R) and CSF2RB, which is a component of multiple cytokine receptors. 295 As mutations in STAT3 and IL6R are associated with distinct immunodeficiency syndromes 296 (39), we analyzed STAT3 signaling in cells treated with IL6 and examined the phosphorylation 297 of Tyrosine 705 (Y705) of STAT3, a marker of its activation. While increased levels of pY705-298 STAT3 were observed in both samples following IL6 treatment, it was markedly reduced in the 299 proband, indicating reduced sensitivity to IL6 (Figure 3D). Together, these data indicated that 300 the cells from the proband showed gene expression changes consistent with immunodeficiency 301 and defective CSR and were less responsive to IL6 cytokine stimulation.





Figure 3: Gene expression differences identify defects in STAT3 signaling in patient derived cell lines. A. Volcano plot of RNA-seq data depicting DEGs in the Proband compared
 to Sibling LCLs. Duplicate samples from each LCL line were analyzed. Full data in online

306 supplemental Table S3. Genes in each enriched category identified in IPA analysis (B) are shown in the indicated color. Hepatic fibrosis genes overlap with Osteoarthritis and are therefore 307 308 not shown. B. Ingenuity Pathway Analysis (IPA) of RNA-seq data is shown. C. Heatmap of 309 individual genes from the indicated enriched pathway are shown. D. Analysis of STAT3 310 phosphorylation on Y705 in response to IL6 in LCLs. Quantification of 4 independent 311 experiments is shown below the western blot. STAT3-p (Y705)/STAT3 was normalized to 312 vinculin and samples were normalized to Sibling -IL6. Statistical significance was determined 313 using an unpaired t test with Welch's correction (\*P<0.05).

314

#### 315 Growth defects and increased DNA damage in a patient-derived cell line

316 To determine the potential impact of the genetic variants and DEGs on cell growth and viability, 317 we compared the growth of the proband- and sibling-derived cell lines by plating the same 318 number of live cells and counting them every 24 hours over 72 hours. Viability at the beginning 319 of the experiment was always >90%. The proband-derived cells showed reduced growth over 320 72 hours, with observable differences after 48 hours (Figure 4A). Flow cytometry analysis of 321 EdU-pulsed cultures showed a reduction of cells in S-phase with a compensatory increase in 322 the G1 population (Figure 4B and 4C). Both the G2/M and sub-G1 populations were also 323 increased in cells from the proband (Figure 4B and 4C). As this suggested potential activation of 324 cell cycle checkpoints, we examined p53 and p21 levels and found that both were upregulated 325 in the proband compared to the unaffected sibling (Figure 4D and 4E).

326

As the increased p53/p21 levels and elevated sub-G1 population suggested stress or DNA damage signaling, we used the alkaline comet assay to examine the LCLs for spontaneous DNA damage and to examine DNA repair following exposure to 2 Gy ionizing radiation (IR). The proband-derived cells showed increased tail moment values in the alkaline comet assay in the absence of IR treatment, indicating elevated levels of DNA damage (**Figure 4F and 4G**).

However, examination using the neutral comet assay did not reveal evidence of increased DNA strand breaks (**Figure 4H**). Consistent with an absence in DSB repair defects, comets induced by IR treatment were resolved similarly to those in the control cell line, indicating that overall DSB repair was functional, suggesting that spontaneous damage may be ssDNA gaps or base damage (**Figure 4G**).



339 Figure 4: Analysis of cell cycle and DNA damage in patient cell lines. A. Relative cell 340 growth of the Proband and Sibling LCLs. N=6. B. Example of representative flow cytometry data 341 to analyze cell cycle in LCLs. Cells were pulsed with 10 µM EdU for 1 hour and stained with 342 DAPI for DNA content. C. Quantification of cell cycle phases from N=2 independent 343 experiments with 2 biological replicates each. Replicates from same experiment indicated with a 344 triangle or circle. D. Western blot analysis of p53 and p21 levels in LCLs. E. Quantification of 345 p53 (N=4) and p21 (N=3) levels from biological replicates. F. Representative images of alkaline 346 comet assays untreated or treated with the indicated dose of ionizing radiation (IR). G. Analysis 347 of tail moment with the indicated treatments and recovery times. Representative of N=2 348 independent experiments. H. Analysis of tail moment in neutral comet assays. Representative of 349 N=2 independent experiments. At least 100 comets were analyzed per condition and 350 experiment. Statistical significance was determined using an unpaired t test with Welch's 351 correction (\*\*\*\*P<0.0001, \*\*\*P<0.001, \*\*P<0.01, \*P<0.05).

352

#### 353 In silico and biochemical analysis of the TLK1 variant

354 As the *TLK1* variant was the best genetic candidate for the observed phenotypes, we analyzed 355 it with a variety of prediction tools to determine if the variant was potentially damaging to TLK1 356 activity (37). The results were variable, with some prediction tools indicating that the variant was 357 damaging and others indicating it was tolerated (online supplementary table S5). Analysis of 358 missense constraint (www.decipher.com) indicated that the kinase domain of TLK1 is highly 359 constrained (online supplementary figure S3). We next analyzed the specific conservation of 360 the Q479 residue using Consurf, including also an additional TLK1 variant that was previously 361 reported in a patient with ASD, p.M566T (Table 1)(29,38). Both residues are located within the 362 kinase domain of TLK1, with Q479 located in a beta sheet of the N-lobe and M566 in an alpha 363 helix of the C-lobe. Both residues scored as highly conserved, indicating that they could be 364 important for kinase activity (Figure 5A).

366	To directly determine if kinase activity was affected, the p.Q479E or p.M566T variants were
367	generated in an expression vector using site-directed mutagenesis. N-terminally Strep-FLAG-
368	tagged TLK1-WT, or the two variants, were expressed in AD-293 cells and affinity purified from
369	cell lysates for <i>in vitro</i> kinase assays using purified ASF1A as a substrate (Figure 5B). A kinase
370	dead mutant of TLK2 (D592V) was used as a negative control for non-specific labeling of the
371	substrate(24). Both the p.Q479E and p.M566T variant proteins showed reduced
372	autophosphorylation activity compared to TLK1-WT and their kinase activity was impaired to
373	similar extent as TLK2-KD compared to TLK1-WT (Figures 5B-C). These results indicated that
374	both variants resulted in severely impaired TLK1 kinase activity.
375	





377 Figure 5: Conservation analysis, kinase activity and proximal interactions of NDD 378 associated TLK1 variants. A. Consurf was used to analyze the level of conservation of the 379 amino acids of human TLK1, with both Q479 and M566 scoring as highly conserved. The 380 predicted structure of the TLK1 kinase domain (Alphafold) is shown with the location of the two 381 residues highlighted in pink(42,43). B. Representative in vitro kinase assay of Streptavidin 382 purified TLK1-WT or NDD variants on purified ASF1A. TLK2-KD is used as a negative control. 383 C. Quantification of N=4 independent kinase assay experiments. D. Western blotting of 384 transfected BioID constructs and biotin labeling imaged with Streptavidin. Ponceau is provided 385 as a transfer control. E. Network depiction of the proximal interactors identified with TLK1 with 386 physical interactions indicated by solid lines. Proteins identified on nascent DNA at replication 387 forks by iPOND-MS and proteins in the Simon's Foundation Autism Research Initiative (SFARI) 388 or DECIPHER databases are indicated(44). Full results provided in online supplementary 389 table S6 and additional data in online supplementary figure S4.

390

#### 391 The NDD-associated TLK1 variants do not strongly alter the proximal proteome

392 We next examined the proximal proteomes of the TLK1 variants using BioID-MS. The BioID 393 enzyme was fused to the N-terminus of the wild type (WT), p.Q479E and p.M566T constructs, 394 and they were expressed by transient transfection in AD293 cells that were pulsed with biotin for 395 24 hours (Figure 5D)(40). Cells were harvested and biotinylated proteins purified using 396 Streptavidin beads. Isolated proteins were subjected to mass spectrometry and analyzed using 397 SAINTexpress to identify proteins specifically labeled by TLK1-WT or either variant allele 398 (online supplementary table S6)(41). The overall network of proximal interactors identified 399 was similar to that we previously observed for TLK2 (Figure 5E and online supplementary 400 figure S4)(24). Few strong differences in proximal interactors with either p.Q479E and p.M566T 401 were identified, including with substrates ASF1A and ASF1B, or DYNLL1/LC8, which we 402 previously identified as a robust interactor of TLK2 (online supplementary figure S4 and table

403 **S6**) (8) (24). These results indicated that while both TLK1 variants had reduced activity, their 404 proximal interactions were not strongly altered, in contrast to what was observed with several 405 TLK2 NDD variants we previously reported(24).

406

### 407 Discussion

408 In this report we describe a proband with a complex phenotype including developmental delay, 409 intellectual disability, leukoencephalopathy, and primary immunodeficiency. Genetic testing 410 identified potential candidate genes, including TLK1 and MDM1. The MDM1 variant was not 411 detectable in LCLs, but total MDM1 expression levels did not appear to be strongly altered at 412 the mRNA or protein level (Figure 2). However, we cannot rule out a potential impact of MDM1 413 haploinsufficiency in other tissues. In mice, a homozygous truncation mutation of *Mdm1* was 414 linked to retinal degeneration(45). Therefore, the optic nerve atrophy or retinal dystrophy 415 observed in the proband could reflect defects in MDM1 function due to heterozygous expression 416 of the truncated allele or haploinsufficiency in eye development. However, we suggest that 417 TLK1 is the most likely genetic contributor to the overall phenotype, particularly the 418 neurodevelopmental outcomes.

419

420 While TLK1-deficient mice do not exhibit any obvious developmental phenotypes, ample 421 evidence exists that kinase dead forms of TLK1 may impact the function of TLK1 or TLK2 422 through heterodimerization via the CC1 motif, resulting in a dominant negative effect(26-28). 423 We examined several substrates of TLK1, ASF1A and NEK1, and did not find a clear difference 424 in their phosphorylation in patient-derived cell lines (Figure 2). However, cells exhibited 425 significant levels of spontaneous DNA damage and growth defects (Figure 4), indicating 426 potential effects on other substrates that we did not analyze in this study. Recent work identified 427 RAD54, a protein involved in homologous recombination of DSBs, as a TLK1 substrate(46). 428 However, the increased DNA damage we observed was not DSBs. TLK1 BioID identified two

429 proteins involved in Mismatch Repair (MMR), MSH3 and POLD1, as proximal interactors 430 (Figure 5). The MMR pathway is involved in the repair of some types of base damage, including 431 that caused by elevated reactive oxygen species, and is also required for CSR(47,48). Thus, 432 TLK1 could potentially play an undefined regulatory role in MMR that is compromised by the 433 variant allele.

434

435 Immunodeficiency has not been reported in mouse models of TLK1 or TLK2 deficiency and is 436 therefore hard to directly link to the heterozygous *TLK1* variant identified in this patient based on 437 current knowledge(8). The immunological presentation, as well as the RNA-seq data generated 438 from PBMCs and LCLs, is consistent with defects in lymphocyte maturation, particularly in B-439 cells, reflecting the proband's status (Figure 3). While the proband initially presented with 440 primary immunodeficiency, T-cells recovered, indicating that remaining issues may be the result 441 of impaired B-cell maturation. CSR is a B-cell specific process that is dependent on a number of 442 non-homologous end-joining (NHEJ) pathway genes that largely, but do not completely, overlap 443 with those required for V(D)J recombination(49). A particular feature of CSR is a distinct 444 requirement for 53BP1 and RIF1 that work with a number of proteins to prevent resection and enforce NHEJ(50). Recent work directly linked ASF1 to RIF1-dependent NHEJ DNA repair(51-445 446 53). We, and others, have identified RIF1 as a proximal interactor with TLK1 and TLK2 (8,52-447 54). Thus, defects in TLK1 that influence ASF1 function in this pathway could potentially impact 448 CSR. Further work remains to determine how important TLK-mediated regulation of ASF1 is to 449 RIF1-dependent NHEJ in the context of CSR or if other key repair proteins are regulated by 450 TLK1.

451

The STAT3 signaling pathway is important for immune system development and emerged as a clearly enriched pathway in our analysis of RNA-seq data. We demonstrated that LCLs are less responsive to IL6 stimulation, likely due to a reduction in IL6R levels (**Figure 3**). Whether this is

a direct result of the TLK1 mutation or reflects the proband's immunodeficient status, we cannot
determine for certain. However, it is notable that a number of other signaling pathways are not
perturbed, including the phosphorylation of two reported substrates, ASF1A and NEK1 (Figure
a), as well as PKC signaling that has been previously linked with neurodevelopmental disorders
(Supplementary Figure S5)(55). Thus, we postulate that alterations in the STAT3 pathway
could potentially contribute to the immune system phenotypes.

461

462 In a previous study of TLK2 variants implicated in MRD57, we observed altered proximal 463 interactions and partial mislocalization of TLK2 variant proteins. In contrast, we did not observe 464 that with either TLK1 variant, as both showed a very similar repertoire of proximal interactors 465 compared to WT. This suggests potential differences in TLK1 and TLK2 regulation that remain 466 to be further explored. Despite this, the proximal interaction profiles of TLK1 and TLK2 were 467 highly similar, further supporting the proposition that they have a large degree of redundancy 468 (Figure 5)(8). As TLK2 mutations clearly impact neurodevelopment, we propose that the 469 p.Q479E variant likely interferes with overall TLK1-TLK2 activity via homo and 470 heterodimerization that impairs chromatin maintenance during brain development. Further 471 analysis of the neurodevelopmental phenotypes of TLK1- and TLK2-deficient mice is therefore 472 warranted.

473

In summary, our data strongly indicates that mutations in *TLK1* are likely to be relevant to rare NDDs and should be considered in clinical diagnostics. Further, TLK1, and potentially TLK2, may impact immune system development in certain contexts and additional work is needed to understand their cellular and developmental roles.

## 479 Data availability statement

- 480 Data are available in public, open access repositories GEO (<u>https://www.ncbi.nlm.nih.gov/geo/</u>)
- 481 ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and PRIDE (https://www.ebi.ac.uk/pride/),
- 482 included in the article or uploaded as supplementary information.
- 483

## 484 **Ethics approval**

- 485 The study protocol was approved by the Mass General Brigham Institutional Review Board and
- 486 informed consent was obtained from the participating family.
- 487

#### 488 Acknowledgements

489 We thank the Stracker lab and L. Deriano for helpful discussions, S. Khurana for antibody 490 optimization, A. De Benedetti for the kind gift of p-NEK1 antibody, D. Zafra and J. Motley for 491 collaboration agreement support, and the IRB Barcelona mass spectrometry core facility and 492 the CCR Genomics facility for technical support. Thank you to the RGP and Broad Institute 493 Center for Mendelian Genomics teams, particularly Melanie O'Leary and Heidi Rehm for project 494 leadership, Ben Weisburd for tandem repeat analysis, Sarah Stenton for mitochondrial genome 495 analysis, and Alba Sanchis-Juan, Harrison Brand, and Michael Talkowski for structural variant 496 analysis.

497

**Funding:** M.V-P. was funded by an FPI fellowship from the Ministry of Science, Innovation and Universities (MCIU: BFU2015-68354-P), T.H.S. was funded by the MCIU (PGC2018-095616-B-100), the 2017 SGR 1089 (AGAUR), FEDER, the Centres of Excellence Severo Ochoa award and the CERCA Programme. M.S.-C. was supported by the IRB Barcelona. T.H.S, M.V-P, J.S. and U.S. were funded by the NIH Intramural Research Program, National Cancer Institute Center for Cancer Research. Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Rare Genomes Project (RGP) and were funded by the National Human

- Genome Research Institute grants UM1 HG008900 (with additional support from the National
  Eye Institute, and the National Heart, Lung and Blood Institute), U01 HG0011755, and R01
  HG009141 and in part by grant number 2020-224274 from the Chan Zuckerberg Initiative DAF,
  an advised fund of Silicon Valley Community Foundation. V.S.G. is supported by NIH NHGRI
  T32 (#1T32HG010464).
- 510 **Competing interests:** none declared.
- 511
- 512 Supplemental Material:
- 513 Supplementary materials and methods.
- 514 **Supplementary Figures**
- 515 Figure S1: Uncropped western blots.
- 516 Figure S2: Uncropped western blots and gels from kinase assays and BioID.
- 517 Figure S3: Decipher analysis of TLK2.
- 518 Figure S4: BioID-western blot analysis and results comparisons.
- 519 Figure S5: Western blotting of PKC substrates.

## 520 Supplementary Tables

- 521 Table S1: Primers used in this study.
- 522 Table S2: Antibodies used in this study.
- 523 Table S3: Differentially expressed genes and IPA analysis (excel).
- 524 Table S4: Analysis of gene specific SNPs in RNA-seq data.
- 525 Table S5: Seqr analysis of the *TLK1* mutation.
- 526 Table S6: BioID-MS data of TLK1 and NDD variants (excel).

- 528
- 529
- 530

531		
532		
533		
534		
535		
555		
536 537	BIDI	lography
538	1	Segura-Bayona S. Stracker TH. The Tousled-like kinases regulate genome and
539	••	enigenome stability: implications in development and disease. Cell Mol Life Sci. 2019. Jul
540		
541	2	Sillió HH Niga EA Identification of human Ast1 chromatin assembly factors as substrates
542	۷.	of Tousled-like kinases. Curr Biol. 2001 Jul 10;11(13):1068–73.
543	3.	Pilyugin M, Demmers J, Verrijzer CP, Karch F, Moshkin YM. Phosphorylation-mediated
544		control of histone chaperone ASF1 levels by Tousled-like kinases. PLoS One. 2009 Dec
545		16:4(12):e8328.
546	4.	Canfield C. Rains J. De Benedetti A. TLK1B promotes repair of DSBs via its interaction
547		with Rad9 and Asf1_BMC Mol Biol_2009 Dec 20:10:110
548	5	De Benedetti A. Tousled kinase TI K1B mediates chromatin assembly in conjunction with
549	0.	Asf1 regardless of its kinase activity BMC Res Notes 2010 Mar 11:3:68
550	6	Klimovskaja IM. Young C. Strømme CB. Menard P. Jasencakova Z. Meilvang J. et al.
551	0.	Tousled-like kinases phosphorylate Ast1 to promote historie supply during DNA
552		replication Nat Commun 2014 Mar 6:5:3394
553	7	Simon B Lou H.I. Huet-Calderwood C. Shi G Boggon T.I. Turk BE et al. Tousled-like
554		kinase 2 targets ASE1 histone chaperones through client mimicry. Nat Commun. 2022
555		Feb 8.13(1):749
556	8	Segura-Bayona S. Knobel PA. González-Burón H. Youssef SA. Peña-Blanco A. Covaud
557	0.	É et al. Differential requirements for Tousled-like kinases 1 and 2 in mammalian
558		development. Cell Death Differ. 2017. Jul 14:24(11):1872–85
559	q	Lee S-B. Segura-Bayona S. Villamor-Pavà M. Saredi G. Todd MAM. Attolini CS-O. et al.
560	5.	Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint
561		and PARP inhibitors. Sci Adv. 2018 Aug 8:4(8):epat/085
562	10	Segura-Bayona S. Villamor-Pavà M. Attolini CS-O. Koenig I.M. Sanchiz-Calvo M. Boulton
563	10.	SL et al. Tousled-Like Kinases Suppress Innate Immune Signaling Triggered by
564		Alternative Longthening of Telemores, Cell Rep. 2020 Aug 4:32(5):107083
565	11	Krause DP Jonnalagadda IC Gatei MH Sillie HHW/ Zhou B-B Nigg EA et al
566		Suppression of Tousled like kingse activity after DNA damage or replication block requires
567		ATM NRS1 and Chk1 Oncogono 2002 Son 4:22(28):5027 27
569	10	Croth A Lukes I Nigg EA Sillió HHW Warnstadt C Partok I at al Human Taualad like
560	12.	Giolin A, Lukas J, Nigy EA, Silije HHW, Weinsleul C, Dallek J, et al. Human rousied like
509		kinases are targeted by an ATM- and ChkT-dependent DNA damage checkpoint. EMBO
570	40	J. 2003 Apr 1;22(7):1676–87. Kelly D. Devey CK. Toyolad like kinese demondent rhear handlation of DadO plays a role in
5/1	13.	Kelly R, Davey SK. Tousled-like kinase-dependent phosphorylation of Rady plays a role in
512		cell cycle progression and G2/W checkpoint exit. PLoS One. 2013 Dec 20;8(12):e85859.
5/3	14.	Awate S, De Benedetti A. ILK1B mediated phosphorylation of Rad9 regulates its
5/4		nuclear/cytoplasmic localization and cell cycle checkpoint. BMC Mol Biol. 2016 Feb
575		9;17:3.
576	15.	Sunavala-Dossabhoy G, De Benedetti A. Tousled homolog, TLK1, binds and

577		phosphorylates Rad9; TLK1 acts as a molecular chaperone in DNA repair. DNA Repair
578		(Amst). 2009 Jan 1;8(1):87–102.
579	16.	Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. The TLK1-Nek1 axis
580	. –	promotes prostate cancer progression. Cancer Lett. 2019 Jul 1;453:131–41.
581	17.	Singh V, Connelly ZM, Shen X, De Benedetti A. Identification of the proteome complement
582		of human I LK1 reveals it binds and phosphorylates NEK1 regulating its activity. Cell
583	4.0	Cycle. 2017 May 19;16(10):915–26.
584	18.	Liu S, Ho CK, Ouyang J, Zou L. Nek1 kinase associates with ATR-ATRIP and primes ATR
585 586	10	for efficient DNA damage signaling. Proc Natl Acad Sci USA. 2013 Feb 5,110(6):2175–80.
500 507	19.	Chen Y, Chen C-F, Riley DJ, Chen P-L. Nek I kinase functions in DNA damage response
501 500		Ech 15:10(4):655, 62
580	20	Nevers PM Bryan IC McEarland IM Woir BA Sizemere AE Xu H et al Computational
500	20.	correction of convinumber offect improves specificity of CPISPP-Cas0 essentiality
590		screens in capper cells. Nat Genet, 2017 Dec:40(12):1770-84
592	21	Rejinders MRF Miller KA Alvi M Goos IAC Lees MM de Burca A et al De Novo and
593	21.	Inherited Loss-of-Function Variants in TLK2: Clinical and Genotype-Phenotype Evaluation
594		of a Distinct Neurodevelopmental Disorder, Am J Hum Genet, 2018 Jun 7:102(6):1195–
595		
596	22.	Woods E. Spiller M. Balasubramanian M. Report of two children with global
597		developmental delay in association with de novo TLK2 variant and literature review. Am J
598		Med Genet A. 2021 Nov 25;
599	23.	Töpf A, Oktay Y, Balaraju S, Yilmaz E, Sonmezler E, Yis U, et al. Severe
600		neurodevelopmental disease caused by a homozygous TLK2 variant. Eur J Hum Genet.
601		2020 Mar;28(3):383–7.
602	24.	Pavinato L, Villamor-Payà M, Sanchiz-Calvo M, Andreoli C, Gay M, Vilaseca M, et al.
603		Functional analysis of TLK2 variants and their proximal interactomes implicates impaired
604		kinase activity and chromatin maintenance defects in their pathogenesis. J Med Genet.
605		2020 Dec 15;
606	25.	Lelieveld SH, Reijnders MRF, Pfundt R, Yntema HG, Kamsteeg E-J, de Vries P, et al.
607		Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability.
608		Nat Neurosci. 2016 Sep;19(9):1194–6.
609	26.	Roe JL, Durfee T, Zupan JR, Repetti PP, McLean BG, Zambryski PC. TOUSLED is a
610		nuclear serine/threenine protein kinase that requires a colled-coll region for
611 612	07	oligomerization and catalytic activity. J Biol Chem. 1997 Feb 28;272(9):5838–45.
012 612	21.	Monuza GB, Hermida D, Pedersen A-K, Segura-Bayona S, Lopez-Mendez B, Redondo P,
015 614		29-0(1)-2525
615	28	20,9(1).2000. Sunavala-Dossabboy G. Li V. Williams B. De Benedetti A. A dominant negative mutant of
616	20.	TLK1 causes chromosome missegregation and anounleidy in normal breast enithelial
617		celle BMC Cell Biol 2003 Oct 28:4:16
618	29	De Rubeis S. He X. Goldberg AP. Poultney CS. Samocha K. Cicek AF. et al. Synaptic
619	20.	transcriptional and chromatin genes disrupted in autism. Nature, 2014 Nov
620		13:515(7526):209–15
621	30	Fromer M. Pocklington A.I. Kavanagh DH. Williams H.I. Dwyer S. Gormley P. et al. De
622	00.	novo mutations in schizophrenia implicate synaptic networks. Nature, 2014 Feb
623		13;506(7487):179–84.
624	31.	Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ. et al. De novo
625		mutations in congenital heart disease with neurodevelopmental and other congenital
626		anomalies. Science. 2015 Dec 4;350(6265):1262–6.
627	32.	Collins RL, Brand H, Karczewski KJ, Zhao X, Alföldi J, Francioli LC, et al. A structural

628 variation reference for medical and population genetics. Nature. 2020 May 629 27;581(7809):444-51. 630 33. Laricchia KM, Lake NJ, Watts NA, Shand M, Haessly A, Gauthier L, et al. Mitochondrial 631 DNA variation across 56,434 individuals in gnomAD. Genome Res. 2022 Mar;32(3):569-632 82. 633 Basu S, Xie X, Uhler JP, Hedberg-Oldfors C, Milenkovic D, Baris OR, et al. Accurate 34. 634 mapping of mitochondrial DNA deletions and duplications using deep sequencing. PLoS Genet. 2020 Dec 14;16(12):e1009242. 635 636 35. Dolzhenko E, van Vugt JJFA, Shaw RJ, Bekritsky MA, van Blitterswijk M, Narzisi G, et al. 637 Detection of long repeat expansions from PCR-free whole-genome sequence data. 638 Genome Res. 2017 Nov:27(11):1895-903. 639 Danecek P, McCarthy SA. BCFtools/csg: haplotype-aware variant consequences. 36. 640 Bioinformatics. 2017 Jul 1;33(13):2037-9. 641 37. Pais LS, Snow H, Weisburd B, Zhang S, Baxter SM, DiTroia S, et al. segr: A web-based 642 analysis and collaboration tool for rare disease genomics. Hum Mutat. 2022 643 Jun;43(6):698–707. 644 Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, et al. ConSurf 2016: an 38. 645 improved methodology to estimate and visualize evolutionary conservation in 646 macromolecules. Nucleic Acids Res. 2016 Jul 8:44(W1):W344-50. 647 39. Spencer S, Köstel Bal S, Egner W, Lango Allen H, Raza SI, Ma CA, et al. Loss of the 648 interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory 649 responses. J Exp Med. 2019 Sep 2;216(9):1986-98. 650 40. Kim DI, Jensen SC, Noble KA, Kc B, Roux KH, Motamedchaboki K, et al. An improved 651 smaller biotin ligase for BioID proximity labeling. Mol Biol Cell. 2016 Apr 15:27(8):1188-652 96. 653 41. Teo G, Liu G, Zhang J, Nesvizhskii AI, Gingras A-C, Choi H. SAINTexpress: 654 improvements and additional features in Significance Analysis of INTeractome software. J 655 Proteomics. 2014 Apr 4;100:37-43. 656 Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold 42. 657 Protein Structure Database: massively expanding the structural coverage of protein-658 sequence space with high-accuracy models. Nucleic Acids Res. 2022 Jan 659 7;50(D1):D439-44. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate 660 43. 661 protein structure prediction with AlphaFold. Nature. 2021 Aug;596(7873):583-9. Wessel SR, Mohni KN, Luzwick JW, Dungrawala H, Cortez D. Functional analysis of the 662 44. 663 replication fork proteome identifies BET proteins as PCNA regulators. Cell Rep. 2019 Sep 664 24;28(13):3497-3509.e4. 665 Chang B, Mandal MNA, Chavali VRM, Hawes NL, Khan NW, Hurd RE, et al. Age-related 45. 666 retinal degeneration (arrd2) in a novel mouse model due to a nonsense mutation in the Mdm1 gene. Hum Mol Genet. 2008 Dec 15;17(24):3929-41. 667 668 46. Ghosh I, Kwon Y, Shabestari AB, Chikhale R, Chen J, Wiese C, et al. TLK1-mediated 669 RAD54 phosphorylation spatio-temporally regulates Homologous Recombination Repair. 670 Nucleic Acids Res. 2023 Jul 13; 671 47. Schrader CE, Edelmann W, Kucherlapati R, Stavnezer J. Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes. J Exp Med. 1999 Aug 672 673 2;190(3):323-30. 674 Ehrenstein MR, Neuberger MS. Deficiency in Msh2 affects the efficiency and local 48. 675 sequence specificity of immunoglobulin class-switch recombination: parallels with somatic 676 hypermutation. EMBO J. 1999 Jun 15;18(12):3484-90. 677 49. Saha T, Sundaravinayagam D, Di Virgilio M. Charting a DNA repair roadmap for 678 immunoglobulin class switch recombination. Trends Biochem Sci. 2021 Mar;46(3):184–99.

- 50. Zimmermann M, de Lange T. 53BP1: pro choice in DNA repair. Trends Cell Biol. 2014
  Feb;24(2):108–17.
- 51. Lee KY, Im J-S, Shibata E, Dutta A. ASF1a Promotes Non-homologous End Joining
  Repair by Facilitating Phosphorylation of MDC1 by ATM at Double-Strand Breaks. Mol
  Cell. 2017 Oct 5;68(1):61–75.e5.
- 52. Tang M, Chen Z, Wang C, Feng X, Lee N, Huang M, et al. Histone chaperone ASF1 acts
  with RIF1 to promote DNA end-joining in BRCA1-deficient cells. J Biol Chem. 2022 Apr
  23;101979.
- 53. Feng S, Ma S, Li K, Gao S, Ning S, Shang J, et al. RIF1-ASF1-mediated high-order
   chromatin structure safeguards genome integrity. Nat Commun. 2022 Feb 17;13(1):957.
- 54. Sukackaite R, Cornacchia D, Jensen MR, Mas PJ, Blackledge M, Enervald E, et al.
  Mouse Rif1 is a regulatory subunit of protein phosphatase 1 (PP1). Sci Rep. 2017 May 18;7(1):2119.
- 692 55. Callender JA, Newton AC. Conventional protein kinase C in the brain: 40 years later.
  693 Neuronal Signal. 2017 Apr 10;1(2):NS20160005.